Eptinezumab
| 證據等級: L5 | 預測適應症: 1 個 |
目錄
Eptinezumab: From Migraine Prevention to Migraine with Brainstem Aura
One-Sentence Summary
Eptinezumab is an anti-CGRP monoclonal antibody used for migraine prevention (episodic and chronic). The TxGNN model predicts it may be effective for Migraine with Brainstem Aura, a specific ICHD-3 migraine subtype, currently supported by 0 clinical trials and 8 publications, most of which address the broader "migraine with aura" population rather than this subtype specifically.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Migraine prevention (episodic/chronic) — general pharmacological use; no Finland license record available |
| Predicted New Indication | Migraine with Brainstem Aura |
| TxGNN Prediction Score | 99.94% (rank 917) |
| Evidence Level | L4 |
| Finland Market Status | ✗ Not Marketed |
| Number of Authorizations | 0 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Currently, detailed mechanism of action data is not available in this evidence pack. Based on known information, Eptinezumab is an anti-CGRP (calcitonin gene-related peptide) monoclonal antibody administered by IV infusion, approved for prevention of episodic and chronic migraine; its efficacy in reducing migraine frequency has been established in Phase 3 trials (PROMISE-1, PROMISE-2).
The proposed new indication, "migraine with brainstem aura" (formerly basilar-type migraine), is a specific ICHD-3 subtype whose aura symptoms (diplopia, dysarthria, vertigo, etc.) are thought to relate more to cortical spreading depression and posterior-circulation mechanisms than to CGRP signaling itself. CGRP's role in the headache phase of migraine is well established, but its causal role in the aura phase remains debated.
Notably, one RCT in this evidence set (PMID 40229719) found that PACAP38-induced migraine attacks occur independently of CGRP signaling, suggesting a CGRP-independent pathway may drive certain aura/trigger mechanisms — this weakens direct mechanistic extrapolation to the brainstem aura subtype. The remaining literature largely covers the broader "migraine with aura" population, so this prediction currently represents an indirect, mechanism-based extrapolation rather than a therapeutic effect validated for this specific subtype.
Clinical Trial Evidence
Currently no related clinical trials registered
Literature Evidence
| PMID | Year | Type | Journal | Key Findings |
|---|---|---|---|---|
| 40229719 | 2025 | RCT (mechanistic) | J Headache Pain | PACAP38-induced migraine attacks are independent of CGRP signaling, suggesting a CGRP-independent pathway may exist alongside CGRP-mediated mechanisms |
| 35302389 | 2022 | Post-hoc Analysis of Phase 3 RCT | Cephalalgia | Post hoc analysis of PROMISE-1/PROMISE-2 evaluating eptinezumab efficacy and safety in patients with migraine and self-reported aura |
| 30725283 | 2019 | Review | Handbook Exp Pharmacol | Overview of CGRP's central role in migraine pathophysiology, including trigeminal system involvement |
| 40341526 | 2025 | Review | Headache | Case series of genetic migraine disorders responsive to CGRP antagonist therapy |
| 33550872 | 2021 | Review | Pain Management | Overview of new acute/preventive migraine treatments including eptinezumab |
| 32699706 | 2020 | Review | Cureus | Review of CGRP antagonists in episodic and chronic migraine management |
| 40191903 | 2025 | Case Report | Rev Neurol | Case of successful management of "wearing-off" effect with eptinezumab in chronic migraine refractory to two subcutaneous CGRP antibodies |
| 35268319 | 2022 | Case Reports + Literature Review | J Clin Med | Case reports and literature review on efficacy of anti-CGRP monoclonal antibodies (including eptinezumab) specifically for migraine aura |
Finland Market Information
Eptinezumab is currently not marketed in Finland; no marketing authorization records are available in this evidence pack.
Safety Considerations
Please refer to the package insert for safety information.
Conclusion and Next Steps
Decision: Hold
Rationale: Evidence level is L4 (mechanism/preclinical-grade extrapolation only) — there are no clinical trials specific to migraine with brainstem aura, and one RCT in the evidence set (PMID 40229719) suggests a CGRP-independent pathway may underlie certain migraine attack/aura mechanisms, weakening the mechanistic case. In addition, Finland/TFDA safety labeling data is flagged as a Blocking data gap (DG001), which prevents even an initial S1 safety evaluation.
To proceed, the following is needed:
- Package insert safety data (warnings, contraindications) — currently a Blocking gap (DG001)
- Confirmed mechanism of action data from DrugBank (currently a High-severity gap, DG002)
- Clinical or observational evidence specific to the migraine-with-brainstem-aura subtype, rather than the broader migraine-with-aura population
- Clarification of Finland market entry status/timeline, since the drug is not currently marketed there
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.